Literature DB >> 9017468

Determination of bezafibrate, ciprofibrate and fenofibric acid in human plasma by high-performance liquid chromatography.

L D Masnatta1, L A Cuniberti, R H Rey, J P Werba.   

Abstract

A selective high-performance liquid chromatographic method to assess either bezafibrate, ciprofibrate or fenofibric acid plasma levels is described. Drugs are extracted with diethyl ether, after acidification with HCL. An isocratic acetonitrile 0.02 M H3PO4 (55:45) mobile phase, a C18 microns) column and UV detection are used. The LOQ found was 0.25 microgram/ml for the three fibrates. Intra- and inter-assay accuracy ranges were 90-107% and 82-111%: 96-115% and 94-107%: 94-114% and 94-126% for bezafibrate, ciprofibrate and fenofibric acid, respectively. Intra- and inter-assay precision (C.V.% ranges) were 1.72-3.06% and 2.66-7.67%: 1.88-4.64% and 0.62-2.99%: 1.26-4.69% and 3.56-7.17% for the three fibrates studied. Its sensitivity, accuracy and precision make it a useful tool for monitoring plasma levels of these drugs in a clinical setting and for research purposes.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9017468     DOI: 10.1016/s0378-4347(96)00254-x

Source DB:  PubMed          Journal:  J Chromatogr B Biomed Appl        ISSN: 1572-6495


  6 in total

1.  Lack of effect of bezafibrate and fenofibrate on the pharmacokinetics and pharmacodynamics of repaglinide.

Authors:  Lauri I Kajosaari; Janne T Backman; Mikko Neuvonen; Jouko Laitila; Pertti J Neuvonen
Journal:  Br J Clin Pharmacol       Date:  2004-10       Impact factor: 4.335

2.  Development and validation of bioanalytical UHPLC-UV method for simultaneous analysis of unchanged fenofibrate and its metabolite fenofibric acid in rat plasma: Application to pharmacokinetics.

Authors:  Rayan G Alamri; Kazi Mohsin; Ajaz Ahmad; Mohammad Raish; Fars K Alanazi
Journal:  Saudi Pharm J       Date:  2016-05-26       Impact factor: 4.330

3.  Development and Validation of RP-HPLC Method for Simultaneous Estimation of Atorvastatin Calcium and Fenofibrate in Tablet Dosage Forms.

Authors:  N Jain; R Raghuwanshi; Deeti Jain
Journal:  Indian J Pharm Sci       Date:  2008 Mar-Apr       Impact factor: 0.975

4.  Quantitative Determination of Ciprofibrate in Tablets by Derivative UV Spectroscopy and RP-HPLC Method.

Authors:  P S Jain; H N Jivani; R N Khatal; S J Surana
Journal:  Indian J Pharm Sci       Date:  2012-03       Impact factor: 0.975

5.  Bezafibrate for X-linked adrenoleukodystrophy.

Authors:  Marc Engelen; Luc Tran; Rob Ofman; Josephine Brennecke; Ann B Moser; Inge M E Dijkstra; Ronald J A Wanders; Bwee Tien Poll-The; Stephan Kemp
Journal:  PLoS One       Date:  2012-07-20       Impact factor: 3.240

6.  Development of self-nanoemulsifying drug delivery systems for the enhancement of solubility and oral bioavailability of fenofibrate, a poorly water-soluble drug.

Authors:  Kazi Mohsin; Rayan Alamri; Ajaz Ahmad; Mohammad Raish; Fars K Alanazi; Muhammad Delwar Hussain
Journal:  Int J Nanomedicine       Date:  2016-06-14
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.